EZH2 and diffuse large B-cell lymphoma: Hence, the BBAP activity likely contributes to chemoresistance in addition to the EZH2 activity, and thus accounts for the difference in the efficacy of GSK126 and ACY-957 on the EZH2GOF DLBCL cells.